Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07OJZ
|
|||
| Former ID |
DNCL003627
|
|||
| Drug Name |
Capmatinib
|
|||
| Synonyms |
1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Approved | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [2] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [3], [4] | ||
| Company |
Incyte
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H17FN6O
|
|||
| Canonical SMILES |
CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
|
|||
| InChI |
1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
|
|||
| InChIKey |
LIOLIMKSCNQPLV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1029712-80-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
56473134, 81021450, 140970141, 144116075, 152159599, 162011567, 162205174, 163643087, 163763208, 165246955, 174006562, 174525845, 185990469, 189622871, 198989884, 210274845, 210280477, 223382041, 223705042, 224332520, 227639025, 242591280, 244011878, 249565587, 249803978, 252110125, 252215585, 252442769, 252451689
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031741) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.